Shavit Capital

MeMed Diagnostics Ltd. is a personalized diagnostics company founded in 2009 and headquartered in Tirat Carmel, Israel. The company specializes in developing innovative diagnostic solutions to enhance patient care and reduce healthcare costs by providing rapid and actionable insights for infectious diseases. Its flagship product, MeMed BV, is a test designed to distinguish between bacterial and viral infections, while the ImmunoDx platform utilizes proprietary biomarkers and algorithms to analyze patients' immune responses, helping physicians make informed antibiotic treatment decisions. MeMed's technologies aim to mitigate the misuse of antibiotics, which is a significant issue globally, leading to ineffective treatments and the emergence of resistant bacterial strains. By addressing the diagnostic gaps in infectious disease management, MeMed seeks to improve clinical outcomes and promote the responsible use of antibiotics.

Lightricks Ltd. is a mobile application developer based in Jerusalem, Israel, specializing in image processing and creativity tools that enhance visual content creation. Founded in 2013 by a team of entrepreneurs with expertise in computer graphics, image processing, machine learning, and artificial intelligence, the company offers a range of popular applications, including Facetune, Enlight, and Beatleap. These applications integrate advanced technologies such as computer vision and augmented reality, allowing users to easily edit and customize their photos and videos. Lightricks' portfolio includes tools for both personal and professional use, catering to individual users and small businesses alike, facilitating engagement and creativity through user-friendly mobile solutions.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

Veev Inc., founded in 2017 and headquartered in Minneapolis, Minnesota, is a building technology company that transforms the home construction and living experience. By utilizing its innovative home operating system, Veev provides clients with room-specific control over lighting, shading, and climate while enhancing security against intrusions and cyber threats. The company's construction approach incorporates modular systems featuring light gauge steel for framing, high-performance acrylic for surfaces, and advanced climate control technologies. Veev focuses on high-performance multifamily housing and accessory dwelling units, boasting a development pipeline of over 230 units, equating to 620,000 gross building square feet. Through comprehensive services that encompass design, permitting, modular construction, and a digital infrastructure, Veev empowers homeowners with enhanced control over their living environments.

Alpha Tau Medical is an Israeli medical device company focused on research, development and commercialization of Alpha DaRT, a diffusing alpha-emitters radiation therapy for solid tumors. The technology delivers localized alpha radiation using interstitial seeds to target cancer cells while aiming to overcome the limitations of traditional alpha therapy. The company is headquartered in Tel Aviv and was founded in 2016, pursuing clinical development with its Alpha DaRT program.

Syqe Medical specializes in transforming cannabis and other psychoactive botanicals into mainstream medical drugs. It offers the Syqe Inhaler Exo, a hospital-grade metered-dose inhaler designed for precise and consistent delivery of therapeutic molecules, enabling effective pain management with reduced psychoactive side effects.

Alpha Tau Medical is an Israeli medical device company focused on research, development and commercialization of Alpha DaRT, a diffusing alpha-emitters radiation therapy for solid tumors. The technology delivers localized alpha radiation using interstitial seeds to target cancer cells while aiming to overcome the limitations of traditional alpha therapy. The company is headquartered in Tel Aviv and was founded in 2016, pursuing clinical development with its Alpha DaRT program.

Anchiano Therapeutics Ltd. is a preclinical biotechnology company focused on discovering, developing, and commercializing small molecule anti-cancer therapies. The company specializes in targeted cancer therapies designed to selectively destroy cancer cells while sparing healthy cells. Its primary development efforts are centered on the Pan-RAS Program, which identifies novel indene-based small molecules that inhibit activated RAS signaling, and the PDE10/ß-catenin program, aimed at selectively inhibiting PDE10 and suppressing Wnt/APC/ß-catenin signaling. Anchiano Therapeutics has a collaboration agreement with ADT Pharmaceuticals to further research these programs. Originally founded in 2004 as BioCancell Ltd., the company rebranded in July 2018 and is headquartered in Cambridge, Massachusetts. The company has developed drug candidates such as BC-819 and BC-821, with BC-819 having completed a Phase IIb clinical trial for bladder cancer.

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.

PolyPid Ltd. is a clinical-stage biopharmaceutical company headquartered in Petach Tikva, Israel, specializing in the development of advanced drug delivery systems based on its proprietary Polymer-Lipid Encapsulation MatriX (PLEX) technology. Founded in 2008, PolyPid's innovative platform allows for the entrapment of various active pharmaceutical ingredients (APIs) within a protective matrix, enabling controlled and prolonged release over extended periods, optimizing therapeutic regimens. The company’s product offerings include D-PLEX, an antibiotic reservoir designed to prevent surgical site infections, and several formulations aimed at addressing bone-related infections, such as BONYPID-1000 and BONYPID-500. PolyPid's technology supports localized drug administration across multiple therapeutic classes, highlighting its versatility in addressing diverse medical needs.

Mapi Pharma is a development-stage pharmaceutical company focused on creating high-barrier-to-entry generic drugs, including complex active pharmaceutical ingredients, formulations, and life cycle management products aimed at substantial markets. With a foundation in robust chemical and pharmaceutical research and development, Mapi leverages its understanding of global markets and regulatory requirements to establish lasting partnerships across various regions. The company is committed to delivering both generic and innovative intermediates and active pharmaceutical ingredients, as well as developing finished dosage forms for its internal programs or as generics of established brands. Headquartered in Israel, Mapi operates R&D facilities in Israel, China, and Germany, and is in the process of constructing an API manufacturing site in Neot Hovav. The company maintains a strong intellectual property position, actively filing patents for its APIs and formulations to protect its innovations.